Details
Stereochemistry | MIXED |
Molecular Formula | C14H29O4S.Na |
Molecular Weight | 316.432 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O
InChI
InChIKey=FVEFRICMTUKAML-UHFFFAOYSA-M
InChI=1S/C14H30O4S.Na/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17;/h12-14H,5-11H2,1-4H3,(H,15,16,17);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H29O4S |
Molecular Weight | 293.443 |
Charge | -1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. Sodium tetradecyl sulfate is the active component of the sclerosant drug Sotradecol. Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. Sotradecol® (sodium tetradecyl sulfate injection) is indicated in
the treatment of small uncomplicated varicose veins of the lower
extremities that show simple dilation with competent valves. The
benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold under the trade-name Fibro-Vein in concentrations of 0.2%, 0.5%, 1.0%, and 3%
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0007596 |
|||
Target ID: CHEMBL4444 |
|||
Target ID: P07225 Gene ID: 5627.0 Gene Symbol: PROS1 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SOTRADECOL Approved UseSotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Launch Date1946 |
Sample Use Guides
Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5866042
Sodium tetradecyl sulfate inhibited flagellation, motility, swarming, and growth of Proteus (inhibitory concentration, 0.1 to 0.5 mmoles per liter). At a concentration of 0.1 mmole per liter, sodium tetradecyl sulfate completely inhibited the motility of Proteus in the liquid medium employed without impairing growth.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:24:59 GMT 2023
by
admin
on
Sat Dec 16 17:24:59 GMT 2023
|
Record UNII |
Q1SUG5KBD6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
12786
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
||
|
NCI_THESAURUS |
C78275
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
||
|
WHO-ATC |
C05BB04
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
||
|
WHO-VATC |
QC05BB04
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201345
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
D012981
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
100000087396
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
SUB10571MIG
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
75273
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
Q1SUG5KBD6
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
23665772
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
755887
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
C66555
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
Sodium tetradecyl sulfate
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
139-88-8
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
130
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
3550
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
DB00464
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
9913
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
Q1SUG5KBD6
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
205-380-3
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
DTXSID3041530
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | |||
|
m10087
Created by
admin on Sat Dec 16 17:25:00 GMT 2023 , Edited by admin on Sat Dec 16 17:25:00 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |